Is Illume Labs profitable in 2026?

No. Illume Labs is pre-revenue as of its July 20, 2026 public beta waitlist launch, with no disclosed pricing, customer logos, or revenue. The 3-founder team has not published any monetization plan or paid product tier as of that date.

Could ChatGPT or Claude replace Illume Labs?

Plausibly. Illume itself names ChatGPT and Claude as its benchmark competitors as of July 20, 2026. Its core feature, text-based health insights over aggregated wearable and lab data, lacks proprietary data or regulatory lock-in that would stop frontier models from replicating it.

Who is Illume Labs' biggest competitor?

Function Health, which raised a $298M Series B in November 2025 at a reported ~$2.5B valuation and already ships AI-generated health insights with clinician review, dwarfing Illume Labs' 3-person, pre-revenue team as of July 2026.

Who owns Illume Labs?

Illume Labs is privately held by its three MIT-founder team, Pari Latawa, Frank Lee, and Jin Wong, and is part of Y Combinator's Summer 2026 batch. No third-party funding amount or valuation has been publicly disclosed as of July 2026.

Does Illume Labs have regulatory approval as a medical device?

No. Illume explicitly describes itself as a 'wellness and longevity tool, not a medical device' as of July 2026, forgoing the clinician-in-the-loop and regulatory posture that peer YC S26 company Clara has adopted.

How does Illume Labs compare to Function Health and Superpower?

Illume Labs is pre-revenue with a 3-person team and a July 2026 beta launch, while Function Health ($298M Series B, Nov 2025, ~$2.5B valuation) and Superpower ($199/year membership with live 24/7 AI chat, per its own June 2026 pricing page) are already operating with paying customers.

YC Summer 2026 · United States

Illume Labs

illumelabs.ai ↗

Illume Labs is an AI companion that reads your wearable, lab, and gene data and texts you health insights.

Little protection left

Assessed 26 July 2026 · Evidence as of 26 July 2026

Not much stands between this business and its pressures.

On the recordSince 26 July 2026 · Checkable from H1 2027 · Every call on the record Checkpoint: Beta-to-GA launch with public pricing, plus any clinical or regulatory positioning shift

The call

Illume is a small, unproven wrapper on user health data competing against clinician-backed, well-funded rivals and the frontier models it names as its own benchmark.

Illume lets you text questions about your health data from wearables, lab tests, and genetic reports. But anyone can build this same thing: ChatGPT and Claude already do it, Function Health has $2.5 billion in backing and clinicians reviewing results, and Apple or Google could add it to their phones tomorrow. The only thing that could change the picture is if Illume gains real doctor involvement, locks in exclusive health data partnerships, or builds something users cannot get from free AI chatbots in the next 12 to 18 months.

Why

AI pressure: ChatGPT and Claude. Illume calls these its benchmark rivals; once frontier models add wearable and lab-data connectors, the text-insight layer becomes free. Could AI do the core job? Yes, likely.

Bigger players: Function Health. Function Health already ships AI insights with clinician review, backed by $298M and a ~$2.5B valuation, live now. Could a giant copy it? Yes, easily.

What protects it. None disclosed yet: Illume holds no exclusive data, no clinician layer, and is still a 3-person team in private beta.

What would change this call

Illume announces GA launch with public pricing within 6 months. Shows whether it can convert waitlist interest into a real paying product.
Function Health, Superpower, or Apple/Google/Samsung add AI chat over aggregated health data. Shows incumbents replicating Illume's core feature with far more capital and users.
Illume discloses a clinician-in-the-loop or regulatory positioning change. Shows whether it adopts the liability posture that could create a real moat.

Key numbers

Function Health: $298M Series B, ~$2.5B valuation (2025-11-01)
Neko Health valuation: ~$1.8B (2026-02-04)
Illume Labs: 3 employees, pre-revenue, waitlist only (2026-07-20)

Named risks

No proprietary health data, clinician oversight, or regulatory posture to block replication. Severity: high
Core text-insight feature could be commoditized by ChatGPT, Claude, or platform owners. Severity: high
Well-funded incumbents (Function Health, Superpower, Neko) can copy feature as low-cost upsell. Severity: high
3-person team with no hiring pipeline limits execution speed against funded rivals. Severity: medium
No published pricing or GA date leaves cash-burn and monetization path unproven. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Function Health	losing to	raised $298M Series B Nov 2025 at ~$2.5B valuation vs Illume's pre-revenue 3-person team as of Jul 2026
Superpower	losing to	already ships live $199/yr 24/7 AI chat membership as of Jun 2026 vs Illume's unpriced beta
Clara	losing to	YC S26 peer with clinician-in-the-loop model and team from $100M-revenue Circle Medical, Jul 2026
Neko Health	losing to	reported ~$1.8B valuation and vertically integrated clinics as of Feb 2026
ChatGPT/Claude	contesting	Illume itself names these as benchmark competitors for its text-insight layer, Jul 2026
Apple/Google/Samsung health platforms	losing to	own default device data pipe, could add native aggregation as feature sprint, Jul 2026

Questions people ask

Is Illume Labs profitable in 2026?: No. Illume Labs is pre-revenue as of its July 20, 2026 public beta waitlist launch, with no disclosed pricing, customer logos, or revenue. The 3-founder team has not published any monetization plan or paid product tier as of that date.
Could ChatGPT or Claude replace Illume Labs?: Plausibly. Illume itself names ChatGPT and Claude as its benchmark competitors as of July 20, 2026. Its core feature, text-based health insights over aggregated wearable and lab data, lacks proprietary data or regulatory lock-in that would stop frontier models from replicating it.
Who is Illume Labs' biggest competitor?: Function Health, which raised a $298M Series B in November 2025 at a reported ~$2.5B valuation and already ships AI-generated health insights with clinician review, dwarfing Illume Labs' 3-person, pre-revenue team as of July 2026.
Who owns Illume Labs?: Illume Labs is privately held by its three MIT-founder team, Pari Latawa, Frank Lee, and Jin Wong, and is part of Y Combinator's Summer 2026 batch. No third-party funding amount or valuation has been publicly disclosed as of July 2026.
Does Illume Labs have regulatory approval as a medical device?: No. Illume explicitly describes itself as a 'wellness and longevity tool, not a medical device' as of July 2026, forgoing the clinician-in-the-loop and regulatory posture that peer YC S26 company Clara has adopted.
How does Illume Labs compare to Function Health and Superpower?: Illume Labs is pre-revenue with a 3-person team and a July 2026 beta launch, while Function Health ($298M Series B, Nov 2025, ~$2.5B valuation) and Superpower ($199/year membership with live 24/7 AI chat, per its own June 2026 pricing page) are already operating with paying customers.

Timeline

2026-07-25YC directory lists Illume Labs headcount at 3, no open job postings
2026-07-22Clara identified as YC S26 peer with clinician-in-the-loop model, from $100M-revenue Circle Medical team
2026-07-20Illume Labs publicly launches private beta waitlist via Launch YC
2026-06-17Superpower publishes pricing comparison, ~$199/year AI chat membership vs Function Health
2026-06-05Modern Med Life ships curated RAG-based AI Longevity Assistant to differentiate from generic chatbots
2026-03-10Function Health v. Superpower deceptive-advertising lawsuit reported by legal analysts
2026-02-04Analyst report frames $3B preventive-health race, cites Function Health and Neko Health valuations
2026-01-26Function Health files lawsuit against Superpower Health in C.D. Cal.
2025-11-01Function Health raises $298M Series B, reported ~$2.5B valuation

Revision history

26 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

Cerenovus Belvedir Hoplite